wegovy glp 1 FDA approves pill and changes everything about GLP-1 drugs GLP-1 obesity drugs cleared of

Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

that bone loss was most pronounced in weight-bearing skeletal sites, with no significant changes in non-weight-bearing areas such as the radius, suggests that mechanical unloading may be a key driver of bone resorption rather than a direct pharmacologic effect of GLP-1 receptor activation

not a product safety finding, but a signal about oversight culture

Doctors typically consider these medications only after other approaches such as nutrition changes, increased physical activity, and behavioral support have not been enough